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Organogenesisrt forming potential (cardiogenic mesoderm) is induced during gastrulation. This
cardiogenic mesoderm later differentiates into heart muscle tissue (myocardium) and non-muscular heart
tissue. Inhibition of Wnt/β-catenin signaling is known to be required early for induction of cardiogenic
mesoderm; however, the identity of the inhibiting Wnt signal itself is still elusive. We have identiﬁed Wnt6
in Xenopus as an endogenous Wnt signal, which is expressed in tissues close to and later inside the
developing heart. Our loss-of-function experiments show that Wnt6 function is required in the embryo to
prevent development of an abnormally large heart muscle. We ﬁnd, however, that Wnt6 is not required as
expected during gastrulation stages, but later during organogenesis stages just before cells of the cardiogenic
mesoderm begin to differentiate into heart muscle (myocardium). Our gain-of-function experiments show
that Wnt6 and also activated canonical Wnt/β-catenin signaling are capable of restricting heart muscle
development at these relatively late stages of development. This repressive role of Wnt signaling is mediated
initially via repression of cardiogenic transcription factors, since reinstatement of GATA function can rescue
expression of other cardiogenic transcription factors and downstream cardiomyogenic differentiation genes.
© 2008 Elsevier Inc. Open access under CC BY license.Introduction
Induction of the heart primordia in all vertebrates occurs in paired
regions of cardiogenic mesoderm located in the lateral mesoderm
(Rafﬁn et al., 2000; Schneider and Mercola, 2001). This cardiogenic
mesoderm includes the precursors of both the muscle forming cells
(myocardium) and non-muscle forming cells (e.g. pericardium). In
Xenopus, these tissues are located in the marginal zone on either side
of the dorsal midline adjacent to the Spemann organizing centre in
gastrula embryos. The cardiac primordia migrate to the ventral
midline where they eventually fuse. Cardiac muscle differentiation
begins around stage 26–27 as detected by the induction of
cardiomyogenic speciﬁc genes, prior to the formation of the linear
heart tube at stage 29 and the beginning of a rhythmic heartbeat at
stage 34 (Mohun et al., 2000).
Speciﬁcation and induction of the primary heart ﬁeld is associated
with the expression of two families of transcription factors in
particular, the Nkx2 homeobox-containing proteins, such as Nkx2.3
and Nkx2.5 (Sparrow et al., 2000) and the GATA family of zinc ﬁnger-
containing transcription factors GATA4, GATA5 and GATA6 (Jiang and
Evans, 1996; Patient and McGhee, 2002). Nkx2 and GATA families ofproject and designed Wnt6
th help from SH (transgenic
nd YDT (histology sectioning).
L and JM carried out the BIO
t.
.
 license.transcription factors are part of the transcription factor network
regulating heart potential and subsequent differentiation. This net-
work regulates the expression of structural cardiomyogenic genes,
such as myosin light chain (MLC2) (Latinkic et al., 2004) and
TroponinIc (Warkman and Atkinson, 2004), which encode the
molecular machinery required for heart muscle function.
The fundamental steps in heart development are remarkably
conserved among vertebrates. For initial induction of cardiogenic
mesoderm, inhibition of canonical Wnt signaling by Dickkopf-1 (Dkk-
1) and Crescent is a critical step in both Xenopus and chick (Marvin
et al., 2001; Schneider and Mercola, 1999, 2001). Experimental xWnt8
and xWnt3A overexpression is able to inhibit cardiogenic marker gene
expression (Marvin et al., 2001), however, so far no particular
endogenous Wnt ligand has been shown to be required to restrict
the size of the cardiogenic mesoderm.
Here we show that Wnt6 regulates heart muscle development in
Xenopus embryos during organogenesis stages using the β-catenin-
dependent canonical Wnt signal transduction pathway. We show that
Wnt6 regulates expression of members of the GATA and Nkx families
of the transcription factor network and subsequently the expression of
downstream structural genes such as MLC2 and TroponinIc.
Materials and methods
Whole-mount in situ hybridization
RNA whole-mount in situ hybridization was performed as
previously described (Lavery and Hoppler, 2008) with a hybridization
178 D.L. Lavery et al. / Developmental Biology 323 (2008) 177–188temperature of 65 °C. Probes were linearized and transcribed using
the High Yield Megascript kit from Ambion (xNkx2.3 with EcoRI and
T7 (Evans et al., 1995); xNkx2.5 with HindIII and T7 (Tonissen et al.,Fig. 1. Development of gain and loss of Wnt6 function tools. (A–D) Axis duplication assay afte
in panel A. Note formation of an ectopic axis with only 20 pg of xWnt6 mRNA (B, indicated w
axis duplication assays with 75 pg xWnt6 mRNA or 200 pg mWnt6 mRNA that co-injection o
vitro transcription and translation assay (TnT); note that xWnt6 protein synthesis (but no
oligonucleotides (MO1, MO2, MO3), but not by the non-speciﬁc Control MO. (F) Western B
antibody raised against chickenWnt6. Detection of ERK2 is used as a protein loading control.
have no effect on ERK2 protein levels. (G) Morphology of stage 43 embryos injected into the
MO3 (I). Note almost identical abnormal morphologies in Wnt6 MO2 and Wnt6 MO3 mo
mesoderm, the somites, the gut, the pigment cells and the tail ﬁn.1994); xGATA4 with XhoI and T3 (Jiang and Evans, 1996); xGATA-6B
with NotI and T7 (Gove et al., 1997); xMLC2with BamHI and T7 (Evans
et al., 1995); xTroponinIc with NotI and T7 (Drysdale et al., 1994)).r injection of xWnt6 mRNA into one ventral blastomere at the 4-cell stage, as illustrated
ith asterisk; compare to uninjected control in panel C). Note in bar chart (D) of Xenopus
f xWnt6 MO3 inhibits axis duplication by xWnt6 mRNA but not by mWnt6 mRNA. (E) In
t control FrzA protein synthesis) is inhibited by Wnt6-speciﬁc morpholino anti-sense
lot analysis of endogenous xWnt6 expression in stage 36 Xenopus embryos using an
Note that xWnt6 MO2 and MO3 signiﬁcantly reduce endogenous xWnt6 expression but
animal pole at the one-cell stage with 30 ng of Control MO (G), Wnt6 MO2 (H) or Wnt6
rphants with obvious defects in the heart-forming region, the eye, the intermediate
179D.L. Lavery et al. / Developmental Biology 323 (2008) 177–188Immunoﬂuorescence staining for Wnt6 and TroponinT
Detection of xWnt6 and xTroponinT protein localization was as
previously described (Lavery et al., 2008).
Morpholino and RNA injections
xWnt6 and mWnt6 capped RNAs were generated using the
mMessage mMachine Transcription kit from Ambion as follows:
xWnt6 (GenBank accession no. EU332159) was cloned into the EcoRI
and XbaI sites of pCS2+, this was then cut with Asp718 and transcribed
with SP6; mWnt6 (Itäranta et al., 2002) was cut with XbaI andFig. 2. xWnt6 is required for regulating heart muscle development. Morphology of the head
sections through the heart forming region at stage 42 (C, D) and whole-mount RNA in situ hy
embryos that were injected into the marginal zone of each blastomere at the two-cell stagew
Note enlarged tissuemass inWnt6morphants in the heart forming region (panel B, compare t
C, scale bar indicates 100 μm, see also panel Q). Also note slightly stronger and extended expr
and much stronger and extended expression of Nkx2.3 (panel J, compare to panel I), Nkx2.5
compare topanel O) (see also panel R). (Q) Percentage bar chart of TroponinT immunohistoche
embryos at stage 42 (see also panels C, D). Note larger TroponinT-expressing tissue inWnt6M
analysis of heart marker expression in xWnt6MO3- and Control MO-injected embryos at stag
strongly increased expression of Nkx2.3, Nkx2.5, TroponinIc (TnIc) and myosin light chain 2
analysis of cardiogenic transcription factor gene expression and heart muscle differentiationm
increased expression of GATA4 in particular at stage 20 and increased expression of heart mtranscribedwith T7.MorpholinoOligonucleotides (MO)were designed
and synthesized by Gene Tools (Wnt6MO1: 5′-GATCTGGACAGGGG-
CAACATGATGG-3′; Wnt6MO2: 5′-TGGGCAGTTAAGTAAAGGGTCCAAC-
3′: Wnt6MO3: 5′-TGGTCTTCAGCGCAATCAAGAGAAG-3′; Control MO:
5′-CCTCTTACCTCAGTTACAATTTATA-3′). All MO and MO/RNA mixes
were heated for 3minutes at 65 °C and placed brieﬂyon ice just prior to
needle loading and injection.
In vitro transcription/translation assay
In vitro translation was performed using the TNT Coupled Trans-
cription/Translation kit from Promega with S35-labeled Methionineand heart forming region at stage 42 (A, B), TroponinT immunohistochemisty analysis of
bridization analysis of marker gene expression at stage 32 (E–N) or at stage 40 (O, P) in
ith 20 ng of either the Control MO (A, C, E, G, I, K, M, O) orWnt6MO3 (B, D, F, H, J, L, N, P).
o panel A) andmore TroponinT-expressingmyocardial tissue (panel D, compare to panel
ession of GATA4 (panel F, compare to panel E) and GATA6 (panel H, compare to panel G),
(panel L, compare to panel K), TnIc (panel N, compare to panel M) and MLC2 (panel P,
mistry analysis of relative size ofmyocardial tissue inWnt6MO- and controlMO-injected
O-injected embryos. (R) Percentage bar chart of whole-mount RNA in situ hybridization
e 32 (see also panels E–P). Note slightly increased expression of GATA4, and GATA6; and
(MLC2) in xWnt6 MO3-injected embryos compared to controls. (S) Bar chart of qPCR
arkers in xWnt6MO3- and ControlMO-injected embryos at stage 20 and stage 32. Note
uscle differentiation markers (MLC2, TnIc) in particular at stage 32 of development.
Fig. 3. Overexpression ofWnt6 during organogenesis stages inhibits heart muscle development. (A) Schematic representation of transgene for concomitant overexpression of xWnt6
and GFP in transgenic Xenopus embryos. (B-E) Identiﬁcation of a non-transgenic control embryo (B, D) versus a transgenic embryo (C, E) induced at stage 22 by heat shock treatment
to overexpress concomitantly GFP and xWnt6 viewed at stage 28 under UV light (D, E; compare with the same embryos viewed under visible light in panels B and C, respectively).
Note only faint background ﬂuorescence (mainly from yolk) in non-transgenic embryo (D), but strong ﬂuorescence due to GFP expression in transgenic embryo (E). External
morphology of whole embryos (F, G) and of the heart forming regions of the same embryos (H, J) at stage 40; TroponinT immunohistochemisty analysis of sections through the heart
forming region at stage 42 (I, K); and analysis of marker gene expressionwith whole-mount RNA in situ hybridization at stage 32 (L–U) in non-transgenic control (F, H, I, L, N, P, R, T)
and xWnt6-overexpressing transgenic embryos (G, J, K, M, O, Q, S, U). Note abnormal morphology in xWnt6-overexpressing embryos, particularly in the eye (G) and the heart-
forming region (G, J). Note much reduced TroponinT-expressing myocardial tissue in xWnt6-overexpressing embryos (panel K, see also panel V). Note signiﬁcantly reduced and
restricted GATA4 (M) and GATA6 (O) expression, dramatic reduction of Nkx2.5 expression (panel Q , but see panel W and panel X) and restricted domains of TroponinIc (TnIc) (S) and
Myosin Light Chain 2 (MLC2) (U) expression in xWnt6-overexpressing embryos. (V) Percentage bar chart of TroponinT immunohistochemistry analysis of relative size of myocardial
tissue in non-transgenic control and xWnt6-overexpressing transgenic embryos; note much smaller TroponinT-expressing myocardial tissue in xWnt6-overexpressing embryos (see
also panels I, K). (W) Percentage bar chart of whole-mount RNA in situ hybridization analysis of heart marker expression in non-transgenic control (NT) and weak or strong xWnt6
overexpression in transgenic embryos. Note reduction of GATA4, GATA6, TroponinIc (TnIc), myosin light chain 2 (MLC2) and generally Nkx2.5 expression in embryos with xWnt6
overexpression. (X) Bar chart of quantitative RT-PCR (qPCR) analysis of heart development marker gene expression in stage 32 embryos. Note reduced expression in xWnt6-
overexpressing embryos, apart from Nkx2.3 and Nkx2.5.
Fig. 4. Overexpression of β-catenin during organogenesis stages inhibits heart muscle development. (A) Schematic representation of transgene for concomitant overexpression of a
stabilized form of β-catenin and GFP in transgenic Xenopus embryos. (B–E) Identiﬁcation of non-transgenic control (B,D) versus transgenic embryos (C, E) induced at stage 22 by heat
shock treatment to overexpress concomitantly GFP and β-catenin, viewed at stage 28 under UV light (D, E, compare with the same embryos viewed under visible light in B and C,
respectively). Note strong ﬂuorescence due to GFP expression in transgenic embryo (E). (F, G) External morphology and TroponinIc expression of non-transgenic control (F) and β-
catenin-overexpressing transgenic (G) embryo at stage 36. Note abnormal morphology in β-catenin-overexpressing embryo, particularly the shortened axis and tail, as well as, much
reduced TroponinIc expression. (H–Q) Analysis of heart marker gene expression with whole-mount RNA in situ hybridization in non-transgenic control (H, J, L, N) and β-catenin-
overexpressing transgenic embryos (I, K, M, O) at stage 32. Note much reduced and restricted GATA4 expression (I), absence of detectable Nkx2.5 (K) and TroponinIc (TnIc) (M)
expression and restricted domain of MLC2 expression (O) in β-catenin-overexpressing embryos. (P) Percentage bar chart of whole-mount RNA in situ hybridization analysis of heart
marker expression in non-transgenic (NT) control embryos, in transgenic embryos with weak GFP and therefore presumably weak β-catenin expression (weak expr.) and in
transgenic embryos with strong GFP and therefore presumably strong β-catenin expression (strong expr.). Note reduction of GATA4, Nkx2.5, TnIc and MLC2 expression in embryos
overexpressing β-catenin. (Q) Bar chart of qPCR analysis of heart marker gene expression in stage 32 embryos. Note reduced cardiogenic gene expression in β-catenin-overexpressing
transgenic embryos.
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plasmid were translated in the presence or absence of 250 ng of the
indicatedMO. 2 μl of the TNT reactionwas run on a pre-cast 4–12% Bis–
Tris SDS PAGE gel (Invitrogen) in MES running buffer (Invitrogen). The
gel was dried onto a piece of Whatman paper and exposed to Kodak
ﬁlm overnight.Western blotting
Protein extracts andWestern blotting was performed as previously
described (Lavery et al., 2008). The rabbit anti-chicken Wnt6 primary
antibody (Zymed, catalog no. 38-3400) was used at a concentration of
2.5 μg/ml and incubated overnight at 4 °C, the rabbit anti-ERK2
182 D.L. Lavery et al. / Developmental Biology 323 (2008) 177–188primary antibody (Santa Cruz catalog no. sc-154) was diluted 1:1000
and incubated at RT for 2 h. Anti-Rabbit-HRP secondary antibody
(Sigma) was used at 1:3000 to detect both Wnt6 and ERK2. The ECL
Western Blotting Substrate from Pierce Biosciences was used for
Chemiluminecent detection. The membranes were stripped using the
Re-Blot Western Blot Recycling Kit (Chemicon).
qPCR analysis of cardiogenic gene expression
Total RNA was extracted using the Qiagen Rneasy Mini kit. A total
of 15 embryos for each experimental condition were harvested but
separated into three separate extractions (5 embryos/tube) and
recombined at the end of the extraction. Generation of cDNA was
done using the QantiTect Reverse Trascription kit from Qiagen. Total
RNA yields were quantiﬁed and normalized using a spectrophot-
ometer so that 1 μg of each sample was used per 20 μl cDNA synthesis
reaction. qPCR was performed using Dynamo Hotstart SYBR green
enzyme from Finnzymes on an Opticon II machine with marker gene-
speciﬁc primers and annealing conditions (xGATA4: forward 5′-GTG-
CCACCTATGCAAGCCC-3′, reverse 5′-TAGACCCACCCGGCGAGAC-3′, at
62 °C (Jiang and Evans, 1996); xGATA6B: forward 5′-CAGTCTCGCTGT-
CAGTGG-3′, reverse 5′-TGAAGGCACTCGCTTCTGAG-3′, at 60 °C; xNkx-2.3:
forward 5′-GTGACAGCCAGTCCTTACACC-3′, reverse 5′-GACATGAAGGAA-
CTGGAGTCC-3′, at 60 °C; xNkx2.5: forward 5′-GAGCTACAGTT-
GGGTGTGTGTGGT-3′, reverse 5′-GTGAAGCGACTAGGTATGTGTTCA-3′,
at 62 °C (Ariizumi et al., 2003); xTpnIC: forward 5′-CCTTGCAGAA-
CACTGTCAGC-3′, reverse 5′-CAGATTAACTGCCTTGGAACG-3′, at 62 °C
(Ariizumi et al., 2003); xMLC2: forward 5′-GAGGCATTCAGCTGTATCGA-
3′, reverse 5′-GGACTCCAGAACATGTCATT-3′, at 60 °C (Small et al., 2005);
xODC: forward 5′-GTCAATGATGGAGTGTATGGATC-3′, reverse 5′-TCCA-
TTCCGCTCTCCTGAGCAC-3′, at 60 °C (De Robertis' Laboratory Home
Page: http://www.hhmi.ucla.edu/derobertis/protocol_page/oligos2004.
pdf). Cardiogenic gene expression was normalized to ODC expression
levels.
Heatshock inducible transgenics
Transgenic embryoswere created and sorted as previously described
(Amaya and Kroll, 1999; Wheeler et al., 2000). Heat treatments were
performed as previously described in Wheeler et al. (2000).
Treatment of Xenopus embryos with BIO and GATA6-GR
For the experiments with the Wnt/β-catenin signaling agonist BIO
(6-bromo-iridium-3′-oxime Meijer et al., 2003; Sato et al., 2004)
embryos were left to develop in 0.1×MMR to embryonic stage 20 (Fig.
5; or the stages indicated in Fig. 3 of the Supplementary data) before
treatment with BIO (6 μM to 12 μM as indicated in the Figure legends)
or MeBIO as a control.
For the rescue experiments with inducible GATA constructs,
embryos were injected with 100 pg of GATA6-GR or GATA4-GR
(Afouda et al., 2005) into themarginal zone of both dorsal blastomeres
at the four-cell stage. Following injection, embryos were incubated in
3% ﬁcoll solution overnight. Then they were placed in fresh 0.1×MMR
until stage 20 when they were placed in 0.1×MMR containing 20 μM
dexamethasone+6 μM BIO (or in controls either DMSO (solvent used
to reconstitute BIO), 20 μM dexamethasone or 6 μM BIO alone) until
stage 32 at which point they were ﬁxed in MEMFA for 1–2 h and
stored in methanol for future analysis by whole-mount RNA in situ
hybridization.
Results
In this investigation, we tested the hypothesis that Wnt6 functions
to regulate heart development and heart muscle differentiation. The
Wnt ligand xWnt6 is expressed in embryonic tissues including theectoderm overlying the developing heart tissue, the endothelial-
endocardium, and the endocardium of the outﬂow tract and
atrioventricular region of the heart at later stages, which correspond
to heart cushion formation (Lavery et al., 2008).
In order to study the function of Wnt6 in Xenopus development,
we developed reagents for gain- and loss-of-function experiments.
We ﬁrst tested the molecular activity of full-length xWnt6 cDNA
(GenBank accession no. EU332159, Lavery et al., 2008) by injecting
xWnt6mRNAventrally in early Xenopus embryos (4-cell stage), which
lead to axis duplication (Figs. 1A–D; as previously shown for mouse
Wnt6 (Itäranta et al., 2002)). This is a functional assay conﬁrming a
fully active molecule, but also providing evidence that xWnt6 is
capable of inducing canonical Wnt signaling (see below).
In order to understand what function xWnt6 may normally play in
development; we performed loss of function studies. A knockdown
strategy was developed involving anti-sense morpholinos (MO) (see
Materials and methods). Three different MOs were tested to examine
which would be the most effective and speciﬁc. Using an in vitro
transcription/translation assay, we demonstrate that all three MOs
inhibit xWnt6 translation, with Wnt6MO2 and Wnt6MO3 being the
most effective (Fig.1E).We next testedWnt6MO2 andMO3 in vivo and
found that they both inhibited translation of endogenous xWnt6 as
detected by Western blot using a Wnt6 antibody raised against chick
Wnt6 (Fig. 1F, for details see Material and methods). Injection of
Wnt6MO2 or Wnt6MO3 into Xenopus embryos induced almost
identical phenotypes (Figs. 2H, I). Both Wnt6 morpholinos cause
morphological defects in the heart forming region (see below),
reduced (or in some cases missing) eyes, enlarged ﬂuid ﬁlled ﬁns;
many suffered from edema; and some had a bent and shortened body
axis, as well as defects in gut looping and cloaca formation. This is not
seen in embryos injected with Control MO (Fig. 2G). Additionally, we
noticed thatWnt6MO2- orWnt6MO3-injected embryos do not swim
or respond to physical stimuli (seeMovies 1–3 in Supplementary data).
The fact that these two morpholinos cause almost identical
phenotypes, despite targeting non-overlapping sequences in the
Wnt6 mRNA, argues for a Wnt6 gene-speciﬁc knockdown and rules
out signiﬁcant off target effects. We chose to use Wnt6MO3 in most
subsequent experiments since it proved more consistent in the
strength of its effects on embryos. Axis duplication assays were used
to further test the speciﬁcity of Wnt6MO3 (Fig. 1D). As expected
Wnt6MO3 completely inhibited ectopic axis induction by xWnt6
mRNA, but had no effect on axis induction by mWnt6 mRNA.
Wnt6 is required for restricting the size of the differentiating heart
muscle
The expression of Wnt6 next to and in the developing heart tissue,
and the obvious morphant phenotype in the heart-forming region
propelled us to investigate a requirement for endogenous Wnt6
function for Xenopus heart development. We used our MO tools to
inhibit endogenous xWnt6 expression and analyzed morphological
phenotype and expression of marker genes associated with heart
development and heart muscle differentiation. We do not detect any
obvious early phenotypes, suggesting that xWnt6 is not required
during early embryogenesis; either because xWnt6 has no early
function or because any early function is redundant with the function
of other Wnt genes, or with other mechanisms. Heart formation and
function is however clearly disrupted in Wnt6MO2- or Wnt6MO3-
injected embryos (Figs. 1H, I; Fig. 2B). The majority of these embryos
do not have a heartbeat, or if they do, it is slow or abnormal (see
movies 4–8 in Supplementary data). The heart is also more difﬁcult to
see than in Control MO-injected embryos, and appears larger and
often also in tighter proximity to the endodermal yolk mass (Figs. 1H,
I; Fig. 2B). Analysis of TroponinT-expressing heart muscle tissue in
Wnt6 morphant embryos shows development of a larger heart with
proportionally larger heart muscle tissue (Figs. 2C, D, Q). We detect no
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viously observed inWnt11-R morphants (Garriock et al., 2005), which
may suggest that Wnt6 is primarily required prior to heart muscle
morphogenesis (see below).
When analyzed by whole-mount RNA in situ hybridization at a
stage when the heart muscle is differentiating (stage 32), there was a
clear up-regulation of many marker genes that are conventionally
associated with heart development and heart muscle differentiation
(Figs. 2E–N, R). Markers for other tissues were found to be unaffected
or even reduced (e.g. the kidney tubule marker NKCC2, data not
shown). Loss of xWnt6 function results in a signiﬁcant increase and
expansion of the expression domains of the Nkx2 family members,
with Nkx2.3 being expanded more laterally while Nkx2.5 expanded
more towards the anterior (Fig. 2L). The cardiomyogenic genes
TroponinIc and MLC2 are also induced by loss of Wnt6 function to
be expressed stronger and in an extended domain (Figs. 2M–P).
Interestingly both GATA4 and GATA6 appear only mildly affected at
this late stage (Figs. 2E–H) this is also evident when represented as a
percentage bar chart (Fig. 2R).
In addition, quantitative PCR analysis of Wnt6MO3 injected
embryos shows a consistent, sequential up-regulation of heart-
development associated genes at different stages of development
(Fig. 2S). Initially we only looked at stage 20 and stage 32 and from this
we can clearly see that at stage 20, expression of both GATA genes is
elevated along with Nkx2.3. GATA 4 appears the most elevated
(approximately 4.5-fold) with Nkx2.5 only mildly effected. By stage 32
the initial increase of earlier heart markers has begun to lessen, while
the later differentiation genes MLC2 and TroponinIc are more than 2-
fold elevated. We repeated this qPCR analysis including more
developmental stages to get a clearer view of the temporal sequence
of effects on these marker genes in response to loss of xWnt6 function
(see Supplementary Fig. 1 in supplementary data), which further
conﬁrms a sequential deregulation of GATA genes initially during late
neurulation, followed by Nkx2 genes and lastly as expected the
differentiation markers MLC2 and TroponinIc. GATA genes have been
shown to be required for maintenance of Nkx2.5 expression and this
early deregulation in GATA4 expression may be responsible for the
increase in the expression of the Nkx2 genes (Nemer and Nemer,
2003; Peterkin et al., 2003). Together, the increase in the GATA and
Nkx2 genes would then be expected to be responsible for the later
induction of the cardiomyogenic genes. Overall, our results show that
xWnt6 normally functions to restrict heart muscle differentiation.
xWnt6 may be required to prevent heart muscle differentiation in
areas of the heart destined to become non-muscle tissue.Fig. 5.Wnt signaling agonist treatment duringorganogenesis stages reduces heartmarker
gene expression, even in Wnt6 morphants. (A, B) Morphology of stage 38 embryos after
control treatment with MeBIO (A) or treatment with theWnt/β-catenin signaling agonist
BIO at 12 μM, from embryonic stage 20 to control stage 32. Note multiple morphological
defects in BIO-treated embryos in addition to absence of any discernable heart; including
enlarged, elongated oval-shaped eyes, which extend toward the anterior; slightly reduced
cement glands; reduced pigmentation; a shortened tail; and skin defects. (C–J) Analysis of
marker gene expression at stage 32withwhole-mountRNA in situ hybridization in control
embryos treatedwith 10 μMMBIO (C, E, G, I) or experimental embryos treatedwith 10 μM
BIO (D, F, H, J) from stage 20 to 32. (K) Percentage bar chart of whole-mount RNA in situ
hybridizationanalysis ofmarkergeneexpression inWnt agonist-treated (BIO) and control-
treated embryos (MBIO). Note that whole-mount RNA in situ hybridization analysis (C–K)
shows that all of themarker genes associatedwith heart development are down-regulated
to a various degree by treatment with BIO. (L) Bar chart of quantitative RT-PCR (qPCR)
analysis of gene expression of heart development (GATA4, GATA6, Nkx2.3 andNkx2.5) and
heart muscle differentiation markers (TroponinIc andMLC2) inWnt agonist- and control-
treated embryos at stage 32. Note that the heartmuscle differentiationmarkers TroponinIc
andMLC2 aremost affected along with Nkx2.5 at this stage of development. (M) Bar chart
of quantitative RT-PCR (qPCR) analysis of marker gene expression at stage 32 in embryos
injected with Wnt6 MO3 and subsequently treated with the Wnt/β-catenin signaling
agonist BIO or MeBIO (10 μM from stage 20). Control embryos were injected with control
MOand treatedwithMeBIO.Note thatBIO-mediatedactivationofWnt/β-catenin signaling
during organogenesis stages rescues to a varying extent the deregulated expression of
heart development and heart muscle marker genes in Wnt6 morphants.Stage-speciﬁc overexpression of xWnt6 inhibits heart muscle
differentiation
The ventral Wnt6 mRNA injection experiments illustrate the
effects Wnt6 overexpression has on early embryonic development
(see above and Fig. 1). However, endogenous xWnt6 is not expressed
at higher levels until organogenesis stages (Lavery et al., 2008), and
our loss of function experiments (see above) indicate that xWnt6 is
not required until these later stages of development. Wnt6 mRNA
injection experiments are unsuitable for studying Wnt function at
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embryonic development would obscure any direct effect Wnt6 might
have on later stages of development. In order to study xWnt6
functional activity during organogenesis stages, we used an inducible
DNA construct in transgenic Xenopus embryos (see Materials and
methods), which allows for stage-speciﬁc overexpression of xWnt6
during organogenesis stages (i.e. stage 22), when Wnt6 function was
found to be required. The full-length xWnt6 was expressed under
control of the Xenopus heat shock protein 70 promoter (Fig. 3A). The
transgenic Wnt6-overexpressing embryos developed reduced eyes
when compared to the non-transgenic control embryos (Figs. 3F, G),
but also an enlarged cavity surrounding a much smaller developing
heart (Figs. 3F, G, H, J, see also movies 9–11 in Supplementary data).
Analysis of TroponinT-expressing heart muscle tissue shows devel-
opment of a smaller heart with less myocardial tissue (Figs. 3K, V). The
overall shape and morphogenetic looping of the heart is also affected
(Figs. 3J, K). When transgenic Wnt6-overexpressing embryos were
analyzed by whole-mount in situ hybridization at stage 32, there was
a clear reduction in expression of all cardiogenic markers tested,
including both genes that are usually associated with cardiac fate
speciﬁcation, such as Nkx2.5, GATA4 and GATA6 (Figs. 3L–Q, W), as
well as later heart muscle differentiation genes, such as MLC2 and
TroponinIc (Figs. 3R–U,W). Markers for other tissues were found to be
unaffected or even up-regulated (e.g. the kidney tubule marker
NKCC2, data not shown). The reduction of Nkx2.5, GATA4 and GATA6
expression is not conﬁned to the prospectivemyocardium tissue but is
more general, affecting the wider expression domain of these
transcription factor genes (Figs. 3L–Q).
The quantitative effects on gene expression were analyzed by
qPCR (Fig. 3X). The majority of the marker genes had reduced
expression as a result of xWnt6 overexpression, with the later
differentiation genes TroponinIc and MLC2 most affected. These
ﬁndings conﬁrm that xWnt6 is capable of restricting heart muscle
differentiation in Xenopus organogenesis. However, with this analysis
both Nkx2.3 and Nkx2.5 expression appear relatively unaffected by
xWnt6 overexpression. This may be explained by the few exceptional
embryos, which we detect by whole-mount RNA in situ hybridization
to have an unusual expansion or up-regulation of Nkx2.5 expression
(Fig. 3W).
We also carried out stage-speciﬁc xWnt6 overexpression experi-
ments at a stage of development (i.e. stage 14) before we detect strong
endogenous xWnt6 expression (Lavery et al., 2008) or defects in our
loss-of-function experiments (see above), and analyzed expression of
GATA6 and MLC2 at differentiation stages (i.e. stage 32) by whole-
mount RNA in situ hybridization (Fig. 2 in Supplementary data). While
overexpression of xWnt6 at this earlier stage is clearly capable of
restricting heart muscle development, the observed repressive effect
is noticeably weaker than when xWnt6 is overexpressed at organo-
genesis stages (see Fig. 3 and above).
Canonical Wnt signaling has been previously invoked to inhibit
heart development during earlier gastrulation stages (Marvin et al.,
2001; Schneider and Mercola, 2001), however our experiments show
for the ﬁrst time that a Wnt ligand is capable of restricting heart
development at the surprisingly late organogenesis stages. This
ﬁnding is consistent with the expression of Wnt6 in the embryo
(Lavery et al., 2008) and the requirement of Wnt6 function for normal
heart development that was revealed in our MO loss-of-function
experiments.Fig. 6. Stage-speciﬁc activation of GATA4 during organogenesis stages rescues reduction of c
Nkx2.5 (A–H), MLC2 (I–P) and TroponinIc (Q–X) expressionwith whole-mount RNA in situ h
U–X) embryos treated from stage 20 with DMSO (A, E, I, M, Q, U); Dexamethasone alone (B, F,
X). Note in embryos with activated GATA4GR increased Nkx2.5 (F), MLC2 (N) and TroponinIc e
reduced Nkx2.5 (C, D, G), MLC2 (K, L, O) and TroponinIc expression (S, T, W); but note restor
activated Wnt/β-catenin signaling is combined with activated GATA4GR. (Y-AA) Bar charts s
TroponinIc (AA) expression in the experiments illustrated in panels A–X (n=number of embCanonical Wnt signaling mediates regulation of cardiomyogenesis
Since xWnt6 is capable of activating the canonical Wnt signaling
pathway as indicated by its ability to induce ectopic axis formation
(see above and Fig. 1), we wanted to examine whether canonical Wnt/
β-catenin signaling also mediates the effects of xWnt6 during heart
organogenesis. We therefore performed stage-speciﬁc β-catenin gain-
of-function experiments in transgenic Xenopus embryos to assess
whether the similar reduction of cardiogenic marker gene expression
occurs, as observed with xWnt6 overexpression.
Stabilized β-catenin (Yost et al., 1996) was overexpressed in
transgenic Xenopus embryos at organogenesis stages (i.e. stage 22)
under control of the Xenopus heat shock protein 70 promoter (Fig.
4A). β-catenin-overexpressing embryos develop with a shortened
body axis; many also have reduced eyes (data not shown). Over-
expression of β-catenin clearly causes reduced expression of all
cardiogenic markers tested to an even greater degree than xWnt6
overexpression. The expression of most of the marker genes is clearly
reduced and in many cases almost absent in the β-catenin transgenic
embryos (Figs. 4H–O). This is also evident when looking at the
percent bar charts (Fig. 4P), with the majority of the β-catenin
transgenic embryos having reduced or absent expression of cardio-
genic genes compared to the control embryos. Markers for other
tissues were found to be unaffected or even up-regulated (e.g. the
kidney tubule marker NKCC2, data not shown). Quantitative PCR
analysis further conﬁrms inhibition of cardiogenic gene expression
caused by overexpression of β-catenin and activation of canonical
Wnt signaling (Fig. 4Q).
We alternatively employed the cell-permeable small molecule BIO
to activate canonicalWnt/β-catenin signaling at organogenesis stages.
BIO has been shown to inhibit GSK3 speciﬁcally, stabilize β-catenin
and thereby activate canonical Wnt signaling (Meijer et al., 2003; Sato
et al., 2004). Treating embryos from stage 20 with BIO results in a
fairly severe phenotype (see Fig. 5). The heart in the BIO-treated
embryos is difﬁcult to discern (Fig. 5B). Consistent with the xWnt6 or
β-catenin overexpression experiments (see above), there is a clear
reduction in expression of all heart development-associated marker
genes in BIO-treated embryos when analyzed bywhole-mount RNA in
situ hybridization (Figs. 5C–K) and qPCR (Fig. 5L). To conﬁrm that we
were activating canonicalWnt/β-catenin signaling at the optimal time
to maximize this inhibitory effect, embryos were treated with BIO at
different stages and allowed to develop to differentiation stage 32 for
analysis of GATA6 and MLC2 expression by qPCR (Fig. 3 in
Supplementary data). Expression of both GATA6 and MLC2 are most
affected (down-regulated) by BIO treatment at stages 20–22,
consistent with the stage-speciﬁc transgenic overexpression experi-
ments (see Figs. 3 and 4).
These experiments show that stage-speciﬁc β-catenin overexpres-
sion and BIO-mediated activation of canonical Wnt signaling can
mediate the effects of overexpressed Wnt6 on heart organogenesis,
but only suggest that endogenous Wnt6 signaling acts via Wnt/β-
catenin signaling in heart organogenesis.We therefore tested whether
the deregulated marker gene expression that we observe as a
consequence of knockdown of endogenous Wnt6 in our morpholino
experiments (above and Fig. 2) can be remedied to any extent by BIO-
mediated activation of Wnt/β-catenin signaling. We ﬁnd indeed that
this artiﬁcial activation of intracellular Wnt signaling with BIO
treatment from stage 20 reduces marker gene expression in Wnt6ardiomyogenic genes caused by activation of Wnt/β-catenin signaling. (A–X) Analysis of
ybridization at stage 32 in uninjected (A–D, I–L, Q–T) and GATA4GR-injected (E–H, M–P,
J, N, R, V); BIO alone (C, G, K, O, S, W); and BIO and Dexamethasone together (D, H, L, P, T,
xpression (V); in embryos with BIO-mediated activatedWnt/β-catenin signaling clearly
ed Nkx2.5 (H) MLC2 (P) and TroponinIc (X) expression in embryos where BIO-mediated
howing the percentage of embryos with high, normal, or low Nkx2.5 (Y), MLC2 (Z) and
ryos assayed for each treatment).
185D.L. Lavery et al. / Developmental Biology 323 (2008) 177–188
186 D.L. Lavery et al. / Developmental Biology 323 (2008) 177–188
187D.L. Lavery et al. / Developmental Biology 323 (2008) 177–188MO3-injected embryos, in the case of the cardiogenic transcription
factors close to (i.e. Nkx2.3 and Nkx2.5) or even below (i.e. GATA4 and
GATA6) the level of expression in control embryos (Fig. 5M). This
result provides much stronger evidence for endogenous Wnt6 to be
signaling via the canonical signal transduction pathway.
Stage-speciﬁc activation of GATA can rescue inhibition of cardiogenic
genes caused by activation of canonical Wnt signaling
In order to investigate mechanisms downstream of Wnt6-
mediated regulation of cardiomyogenesis, we tested whether rein-
stating myogenic transcription factor activity could rescue the
expression of cardiomyogenic differentiation markers. We utilized
BIO to activate Wnt/β-catenin signaling and dexamethasone-induci-
ble xGATA4 and xGATA6 constructs (xGATA4 and xGATA6-GR, Afouda
et al., 2005, which we have recently discovered to rescue cardiogenic
development in embryonic explants (Afouda et al., 2008)). As
expected, expression of Nkx2.5, MLC2 and TroponinIc were all
inhibited by activation of canonical Wnt signaling (Figs. 6G, O, W;
Figs. 7G, O, W). However, reinstating either GATA6 or GATA4 activity is
capable of rescuing the expression of the other cardiogenic transctip-
tion factor Nkx2.5 and the differentiation markers MLC2 and
TroponinIc (Figs. 6H, P, X; Figs. 7H, P, X). There was virtually no
rescue in the absence of dexamethasone, conﬁrming the integrity of
our inducible GATA constructs. These results suggest that the
repressive function of Wnt6 or of canonical Wnt signaling is primarily
mediated via reduced expression of cardiogenic transcription factors,
such as GATA.
Discussion
Wnt/β-catenin signaling has previously been inferred to have an
inhibitory role during early heart development, because the
expression of known Wnt signaling inhibitors such as Dickkopf-1
(Dkk-1) and Cerberus are required for cardiogenic mesoderm
induction (Marvin et al., 2001; Schneider and Mercola, 1999,
2001). In this investigation we have identiﬁed Wnt6 as an en-
dogenous regulator of heart muscle development, but during the
later stages of organogenesis.
Our xWnt6 knockdown experiment shows that xWnt6 is required
to restrict heart muscle differentiation. However, deregulation of
expression of genes associated with heart development in general and
heart muscle differentiation in particular is not limitless. We consider
three possible explanations for this ﬁnding: ﬁrst, other Wnt ligands
may function partially redundantly with xWnt6 to restrict cardio-
myogenesis; second, other molecular mechanisms contribute towards
restricting cardiomyogenesis and third, the developmental potential
to differentiate into heart muscle is already restricted to some extent
in the tissue. We believe there is supporting evidence for any of these
three possibilities. xWnt6 is not the only Wnt expressed near the
developing heart; Wnt2 is expressed dorsal to the heart-forming
region (Landesman and Sokol, 1997) and could therefore contribute
towards restricting cardiomyogenesis. However, cardiomyogenesis in
this part of the heart ﬁeld has also been shown to be regulated by
other mechanisms, i.e. Notch signaling (Rones et al., 2000) and hence
there may be no need to invoke the function of other Wnt ligands in
this process. There is also ample evidence that the heart forming
potential is restricted to the cardiac mesoderm (or heart ﬁeld) atFig. 7. Stage-speciﬁc activation of GATA6 during organogenesis stages rescues reduction of ca
Nkx2.5 (A–H), MLC2 (I–P) and TroponinIc (Q–X) expressionwith whole-mount RNA in situ h
U–X) embryos treated from stage 20 with DMSO (A, E, I, M, Q, U); Dexamethasone alone (B, F,
X). Note in embryos with activated GATA6GR only slightly increased Nkx2.5 (F), MLC2 (N) a
signaling clearly reduced Nkx2.5 (C, D, G), MLC2 (K, L, O) and TroponinIc expression (S, T, W);
BIO-mediated activated Wnt/β-catenin signaling is combined with activated GATA6GR. (Y-A
MLC2 (Z) and TroponinIc (AA) expression in the experiments illustrated in panels A–X (n=nstages of development that proceed those during which we
demonstrate xWnt6 signaling is required for further restriction of
cardiomyogenesis (Garriock and Drysdale, 2003; Rones et al., 2000).
Conventionally, heart development is described as having an early
phase when heart potential is induced during gastrulation and a later
phase when tissue differentiation proceeds during organogenesis
stages. Our overexpression experiments show that Wnt6 is capable of
inhibiting heart muscle development relatively late, immediately
prior to cardiomyocyte differentiation, which might be taken to
suggest that Wnt signaling regulates heart muscle differentiation
directly. However, our loss-of-function experiments reveal deregula-
tion of cardiogenic transcription factor gene expression from early
organogenesis stages clearly preceding the enhanced expression of
structural genes associated with heart muscle differentiation during
later organogenesis. Our overexpression experiments always show
reduced expression of transcription factor genes, which are usually
associated with the regulation of cardiogenic potential. Furthermore,
this reduction in expression of cardiogenic transcription factor genes
is evident in a wide area of tissue that extends beyond the prospective
myocardium. This ﬁnding suggests that even at this relatively late
stage, Wnt6 primarily regulates cardiogenic potential, which subse-
quently leads to restricted heart muscle differentiation.
Does xWnt6 also function at earlier stages to regulate the size of
the cardiac mesoderm (or heart ﬁeld)? Our xWnt6 knockdown
experiments reveal consequences for heart-speciﬁc gene expression
and subsequent cardiomyogenesis only from late neurula and early
organogenesis stages onwards. Although xWnt6 expression levels are
much lower at earlier stages of development (Lavery et al., 2008), our
experiments cannot rule out an earlier role for xWnt6 in regulating
heart development, which is not revealed in our knockdown
experiments because of redundancy with other Wnt ligands or with
other molecular mechanisms. Similarly it is likely that Wnt6 has later
roles in heart development. We ﬁnd xWnt6 expression in distinct
tissues of the more developed heart, such as the cardiac cushions
(Lavery et al., 2008). However, any possible phenotypes in those
tissues are difﬁcult to study due to the earlier phenotypes described
here resulting from our xWnt6 gene knockdown. Such an additional
requirement for xWnt6 function at later stages of heart development
may also account for why we often ﬁnd in our xWnt6 knockdown
experiments an enlarged heart that is not properly beating. The Wnt/
β-catenin signaling pathway itself has clearly several distinct func-
tions at different stages of vertebrate heart development (Lickert et al.,
2002; Marvin et al., 2001; Naito et al., 2006; Schneider and Mercola,
2001; Ueno et al., 2007).
What are the means through which Wnt signaling restricts
cardiomyogenesis? We ﬁnd that deregulated increased GATA gene
expression is the earliest response to Wnt6 knockdown and that
stage-speciﬁc reinstatement of GATA4 or GATA6 function is capable of
relieving the repression of cardiomyogenic genes caused by activation
of canonical Wnt signaling. This suggests that canonical Wnt signaling
is acting at least initially, on regulating expression of cardiogenic
transcription factors, even at these relatively late stages just prior to
differentiation.
Generally what has been discovered for Xenopus embryonic
development proved relevant to the understanding of mammalian
embryonic development. Organogenesis stages are also among the
most conserved stages of vertebrate development. However to date no
expression has been described for Wnt6 in the developing mouserdiomyogenic genes caused by activation of Wnt/β-catenin signaling. (A–X) Analysis of
ybridization at stage 32 in uninjected (A–D, I–L, Q–T) and GATA6GR-injected (E–H, M–P,
J, N, R, V); BIO alone (C, G, K, O, S, W); and BIO and Dexamethasone together (D, H, L, P, T,
nd TroponinIc expression (V); in embryos with BIO-mediated activated Wnt/β-catenin
but note restored Nkx2.5 (H) MLC2 (P) and TroponinIc (X) expression in embryos where
A) Bar charts showing the percentage of embryos with high, normal, or low Nkx2.5 (Y),
umber of embryos assayed for each treatment).
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requirement of Wnt6 for mouse heart development.
In conclusion, our investigation shows that Wnt6 functions to
regulate heart muscle development. An inhibitory role for canonical
Wnt signaling in heart development was previously suspected from
the heart development-promoting effect of known inhibitors of Wnt
signaling at early stages of development. Wnt6 is the ﬁrst Wnt ligand
shown to be required for restricting heart development. Surprisingly,
this requirement is during the later stages of organogenesis immedi-
ately prior to differentiation of heart muscle (cardiomyogenesis); and
the initial target of regulation even at these advanced stages of heart
development are the cardiogenic transcription factors, which were
generally thought to regulate cardiogenic cell fate and subsequent
heart muscle differentiation.
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